TAK: Three White Soldiers detected on 17 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 45 setups from the 17 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 17 Nov 2026, our scan flagged TAK as a three white soldiers setup scoring 77 out of 98 (Good tier), with a 72% win probability based on our historical pattern database and a 1.52 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $21.59, the conservative target is $22.90 with a stop at $20.73.

77 of 98
Good
72%
High
1.52 : 1
$1.31 to target $0.86 to stop
Swing Trading Plan
Entry
$21.59
$22.90
$20.73
3-9 trading days
Exp. Reward
+$0.78
Exp. Risk
-$0.14

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
TAK is forming a three white soldiers pattern at $21.59, just 1.24% below its 52-week high. The structure score of 13.85/15 and volume score of 12.0/12 indicate solid candle formations with above-average support. The breakout score of 10.21/13 reflects a measured-move target of $22.90, requiring just a 6% advance from current levels with key support anchored at $17.95. RSI at 72 signals overbought conditions. The overall score of 77.06/98 and win probability of 71.88% suggest above-average pattern reliability despite the stretched technical environment.
Stock Context
TAK beat Q2 estimates with adjusted earnings of 48 cents per share versus consensus of 31 cents, and sales reached $7.457 billion, beating the $7.19 billion estimate. The company raised fiscal 2026 core earnings guidance from 472 yen to 482 yen per share and revenue guidance from 4.64 trillion yen to 4.70 trillion yen. CEO Julie Kim noted the company is managing headwinds from mature and off-patent products, primarily Vyvanse generics. Recent pipeline progress includes ORZEYFUL approval in the U.S., Japan, and China, MIMRYLO's U.S. launch, and regulatory progress on zasocitinib. Most recently, Takeda announced on November 13, 2026, the launch of ELAHERE in Japan for platinum-resistant recurrent ovarian cancer. Zacks upgraded TAK to "strong-buy" on October 30th, though Wall Street Zen downgraded from "buy" to "hold" on November 15th.
What to Expect
A successful three white soldiers breakout would see TAK clear $21.86 resistance on strong volume confirmation (above the 1.08x relative volume threshold). The measured move target sits at $22.90, implying approximately 6% upside from pattern completion. Given the 71.88% win probability and structure score of 13.85, historical data suggests this setup has above-average reliability. The invalidation level—where this pattern fails—sits at $17.95 key support, representing a 16.8% downside from the current price. Volume relative to the 20-day average of 3.02M shares is trending slightly elevated at 1.08x, adequate for confirmation.
Risk Factors
Several headwinds warrant caution. RSI at 72 indicates overbought momentum, elevated risk of pullback. Mature product headwinds remain unresolved, pressuring core growth despite new launches. The broader market regime is bearish with regime score of -0.3, contrasting the bullish sector backdrop (0.89), creating conflicting directional signals. Takeda's Capital Markets Day on December 11, 2026, could act as a potential volatility catalyst. With beta of only 0.17, TAK moves 83% less than the market, limiting upside acceleration. Prior pattern on this stock (bull flag formed October 5) showed only weak strength (24.0 score), suggesting recent price action may be prone to reversal. Volatility at 22.46% is notably elevated for a low-beta defensive name.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is TAK a good swing trade?
TAK scored 77 out of 98 on our three white soldiers scan, with a 72% historical win probability over a 3-9 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $21.59, with a conservative target of $22.90 and a stop loss at $20.73.
What would invalidate this three white soldiers setup?
A close below the stop loss at $20.73 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical three white soldiers setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish -0.30
-1.0 0 +1.0
Health Care Sector
Bullish 0.89
-1.0 0 +1.0
Other Patterns Detected Today
Bull Flag
29 days in pattern
Weak 24.0
Rounding Bottom
158 days in pattern
Good 33.4
Overall Score
36 of 40
Exceptional
Pattern Quality
16 of 20
Strong
Setup
15 of 20
Good
R/R
10 of 18
Fair
Context
Pattern Quality Score
14 of 15
Exceptional
Structure
10 of 13
Good
Breakout
12 of 12
Exceptional
Volume
Recent Performance
+2.4%
1W
+3.5%
2W
+9.8%
1M
+19.6%
3M
Momentum & Trend
RSI (14)
72.0
Overbought
MACD Histogram
+0.01
Bullish
Bollinger Band Position
94.5%
Upper Band
Volatility & Risk
20-Day Volatility
0.22
Moderate
ATR %
2.4%
Medium
Beta
0.17
Defensive
Volume Analysis
Volume Ratio
1.08x
Average
20-Day Avg Vol
3.0M
shares / day
Current Volume
3.3M
shares traded
Price Levels
Target
$22.90
52W High
$21.86
Resistance
$21.86
Current
$21.59
Stop Loss
$20.73
Support
$17.95
52W Low
$13.91
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.